Navigation Links
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
Date:5/4/2008

- In Clinical Trial, Motavizumab Reduced Hospitalizations Due to

Respiratory Syncytial Virus by 83 Percent Compared to Placebo -

HONOLULU, May 4 /PRNewswire/ -- MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody (MAb) that is being evaluated for its potential to prevent serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. Kate O'Brien, M.D., M.P.H., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, is the study's principal investigator. Aruna Chandran, M.D., M.P.H., a trial co-investigator, presents the data today at the Pediatric Academic Societies (PAS) Annual Meeting in Honolulu, HI.

This randomized Phase 3 study demonstrated that motavizumab reduced hospitalizations due to RSV by 83 percent as compared to placebo (8.3 percent in placebo arm versus 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

The randomized, double-blind Phase 3 study involving 1,410 full-term healthy infants less than six months of age in some Southwest Native American populations was designed to compare monthly intramuscular injections of motavizumab against placebo. In previous epidemiologic studies these populations were shown to have high rates of hospitalization due to RSV. This study confirmed the high rates of serious RSV disease in this population. An interim analysis, reviewed by an independent data safety monitoring committee, concluded there was statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... senior health policy analyst for Consumers Union, will urge Congress ... before the House Energy & Commerce Health Subcommittee.  The ... of the Medical Device User Fee Act beginning at 10:15 ... Recent safety problems with metal hip implants ...
... LA JOLLA, Calif., Feb. 15, 2012 Celladon ... and development of innovative treatments for cardiovascular diseases, ... million equity financing to advance its lead investigational ... failure. The financing was led by new investor ...
Cached Medicine Technology:Consumers Union to Testify for Stronger Medical Device Safety Oversight at House Hearing Today 2Consumers Union to Testify for Stronger Medical Device Safety Oversight at House Hearing Today 3Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 2Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 3
(Date:7/9/2014)... Australian researchers reveal that sudden, acute episodes of low ... as temperature, humidity, air pressure, wind direction and precipitation. ... a journal of the American College of Rheumatology (ACR), ... increases with higher wind speed or wind gusts, but ... World Health Organization (WHO) nearly everyone experiences low back ...
(Date:7/9/2014)... School of Medicine at the University of Pennsylvania in ... an $8 million grant from the National Cancer Institute ... (PDT) in patients with malignant pleural mesothelioma, a rare, ... in the lining of the lungs and is caused ... fund a clinical trial and additional studies looking at ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Ph.D., a senior research scientist in the Department of ... Park, has been chosen to receive a 2009 Astellas ... Chemical Society, is given to individuals who have made ... their work in the chemical and related sciences. ...
... ... Carestream Health will Share Insights and Best Practices for Developing an Intelligent Portfolio ... Austin, Texas ... management solutions, will host a case study webinar discussing best practices for increasing ...
... , U.S. Rep. ... , WASHINGTON, Dec. 10 The Federal Employees Health Benefits ... American Federation of Government Employees, (AFGE) "Inside Government" radio program. The ... on Federal News Radio at www.federalnewsradio.com ...
... Speaker Nancy Pelosi issued the following statement today applauding ... Appropriations Act lifting the ban on federal funding for syringe ... bill passed the House this afternoon by a vote of ... syringe exchange could not be more clear. As Dr. Anthony ...
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that ... Morgan Healthcare Conference on Monday, January 11, 2010 at 2:30 p.m. ... Francis Hotel in San Francisco, CA. , Individuals can ... section of the company,s web site www.savient.com . Following ...
... may help avert drug errors, study authors suggest, , ... finds that even adults who know what medicines they ... getting in the hospital. , Forty-four percent of patients ... that was not actually prescribed. A patient who normally ...
Cached Medicine News:Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 3
... Delivers the advanced performance benefits ... strength, versatility, and durability ... that augments the effectiveness of ... floor reconstruction. Comprised of sterile, ...
... (also known as the VOCARE) Bladder System ... used by people with spinal cord injuries ... demand. A secondary use of the device ... promote penile erection.,The Bladder System includes surgically ...
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... Urinary Control offers a revolutionary approach ... symptoms of overactive bladder, including urinary ... urgency-frequency alone or in combination in ... not tolerate more conservative treatments. Medtronic ...
Medicine Products: